

Message

**From:** Gavin Dabrera [/O=PUBLIC HEALTH ENGLAND/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=GAVIN DABRERAE74]  
**Sent:** 01/03/2016 2:23:47 PM  
**To:** 'Wight, Ailsa' [ailsa.wight@dh.gsi.gov.uk]; 'Tunbridge, Graeme' [Graeme.Tunbridge@dh.gsi.gov.uk]; **Name Redacted** [Name Redacted]@dh.gsi.gov.uk  
**CC:** Nick Phin [nick.phin@phe.gov.uk]; Richard Pebody [richard.pebody@ukhsa.gov.uk]; **Name Redacted** [Name Redacted]@dh.gsi.gov.uk  
**Subject:** RE: middle east respiratory syndrome coronavirus - notifications

Thanks we can provide a written note for justification if needed.

We may need a little notice about the intended dates for those changes, so that our information systems can be updated as appropriate.

Kind regards

Gavin

---

**From:** Wight, Ailsa [mailto:ailsa.wight@dh.gsi.gov.uk]  
**Sent:** 01 March 2016 14:20  
**To:** [See recipients listed above]  
**Cc:** [See recipients listed above]  
**Subject:** RE: middle east respiratory syndrome coronavirus - notifications

Great minds! We are already thinking along the same lines and have raised the issue with our lawyers, who advise it should be fairly straightforward to add to the relevant regs. We hope there will be time for legal to do that during 16-17. WE will need to involve you in the process (justification etc) and also in publicising any change later on, so will keep in touch on progress over coming months.

Nick  
Just fyi, we'll probably add CPE (and possibly other aspects of AMR) to the lab list too. Who is the best contact in PHE for that?

Bw  
ailsa

 Ailsa Wight  
Deputy Director  
Infectious Diseases and Environmental Hazards  
Public and International Health Directorate  
101 Richmond House, 79 Whitehall, London, SW1A 2NS  
E: [ailsa.wight@dh.gsi.gov.uk](mailto:ailsa.wight@dh.gsi.gov.uk) T: **Irrelevant & Sensitive**  
Follow us on Twitter @DHgovuk

---

**From:** Gavin Dabrera **Irrelevant & Sensitive**  
**Sent:** 01 March 2016 14:00  
**To:** Wight, Ailsa; Tunbridge, Graeme  
**Cc:** Nick Phin; Richard Pebody  
**Subject:** middle east respiratory syndrome coronavirus - notifications

Dear Ailsa and Graeme

I trust this email finds you well

As you will be aware, over three years have now passed since the first UK case of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was imported and as disease activity continues in the Middle East there is unlikely to be any significant reduction in the overall risk in the medium term.

As just one part of our broad MERS-CoV preparedness efforts, we have emphasised the need for prompt effective infection prevention and control measures, not only for confirmed cases but also for possible cases while MERS-CoV test results are awaited. The aim of this is to prevent wider nosocomial spread and therefore, hospital-related outbreaks. To achieve this, PHE health protection teams have been informed when testing has been agreed so that infection control advice can be provided quickly. These efforts have been greatly aided by the provision of MERS-CoV testing by PHE regional microbiology laboratories, which facilitates timely information flow to PHE health protection teams.

This testing will continue to be available in the future. However, we are aware that CE-marked commercial testing kits are now available for human diagnostic laboratories to be used. There is now the very real possibility that diagnostic MERS-CoV testing could occur in the near future outside of PHE laboratories. This would potentially circumvent the established information flows from PHE regional microbiology laboratories.

To address these new developments, we would recommend that MERS-CoV becomes a notifiable disease and a notifiable causative agent. This would address this problem by ensuring that registered medical practitioners have a duty to notify a possible MERS-CoV case on clinical suspicion. This would enable the local PHE health protection team to intervene early to ensure adequate MERS-CoV infection control procedures were in place. Notifiable causative agent status would provide additional reassurance that local positive results are reported appropriately and such specimens are referred onwards to the reference laboratory for confirmation.

These recommended changes would not only enable public health action but also provide assurance that we would be able to meet our surveillance and reporting commitments as per the International Health Regulations.

I would be grateful if you would be able to advise us of your views on the above recommendations, and what the next steps might be if you agree with these.

Thanks in advance for your help with this matter

Kind regards

Gavin Dabrera

Interim Head, Legionella and Influenza Preparedness and Response Section,  
Respiratory Diseases Department  
*National Infections Service*  
Public Health England

**Irrelevant & Sensitive**

[gavin.dabrera@phe.gov.uk](mailto:gavin.dabrera@phe.gov.uk)

[www.gov.uk/phe](http://www.gov.uk/phe) Follow us on [Twitter @PHE\\_uk](https://twitter.com/PHE_uk)

**Protecting and improving the nation's health**

\*\*\*\*\*

The information contained in the EMail and any attachments is confidential and intended solely and for the attention and use of the named addressee(s). It may not be disclosed to any other person without the express authority of Public Health England, or the intended recipient, or both. If you are not the intended recipient, you must not disclose, copy, distribute or retain this message or any part of it. This footnote also confirms that this EMail has been swept for computer viruses by Symantec.Cloud, but please re-sweep any attachments before opening or saving. <http://www.gov.uk/PHE>

\*\*\*\*\*

This email was scanned by the Symantec anti-virus service

In case of problems, please call your IT support helpdesk.

---

This e-mail and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this e-mail is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received.

---

Incoming and outgoing e-mail messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's e-mail policy click here <http://www.dh.gov.uk/terms>

---

This email was scanned by the Symantec virus scanning service and was certified virus free.  
Communications may be automatically logged, monitored and/or recorded for legal purposes.